e-learning
resources
Vienna 2012
Monday, 03.09.2012
Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience
C. Gomez, C. Taillé, R. Lazor, B. Crestani, V. Cottin, M. Reynaud-Gaubert (Marseille, Paris, Lyon, France)
Source:
Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Session:
Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Session type:
Poster Discussion
Number:
1776
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Gomez, C. Taillé, R. Lazor, B. Crestani, V. Cottin, M. Reynaud-Gaubert (Marseille, Paris, Lyon, France). Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience. Eur Respir J 2012; 40: Suppl. 56, 1776
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Long-term sirolimus treatment in lymphangioleiomyomatosis
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Source: Eur Respir J 2014; 43: 1691-1697
Year: 2014
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial
Source: Eur Respir J 2016; 47:1452-1460
Year: 2016
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension
Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020
Year: 2021
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM)
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019
Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy.
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Belgian prospective, multicenter, observational study of patients with malignant pleural mesothelioma treated with pemetrexed plus platinum
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Effect of bosentan on MMP-7 levels as add-on therapy in idiopathic pulmonary fibrosis. A prospective study
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept